In patient-derived tumor cells (PDCs) with nuclear receptor coactivator 4 (NCOA4)-RET fusion obtained from the brain metastasis of a 63-year-old mCRC patient, vandetanib revealed a significant antitumor effect in terms of cell viability to CRC-PDCs [110]. This evidence concerns the gene RET and colorectal carcinoma.